SAIMSARA Journal

Machine Generated Science • ISSN 3054-3991

Stem Cell Therapy for Cardiovascular Disease, Heart Failure, and Refractory Angina: Scoping Review with ☸️SAIMSARA.

Cardiac & Vascular Health icon

Cardiac & Vascular Health

Issue 1, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsarac42ee27d

Editorial note
• Last update: 2026-05-10 08:44:21
What is this paper about
Stem cell therapy for cardiovascular disease is biologically compelling but clinically heterogeneous: this map separates the strongest human signals from protocol-only, preclinical, safety, and mechanistic evidence. The full SAIMSARA evidence map gives humans and AI agents a structured, reference-linked view of LVEF signals, refractory-angina outcomes, cell retention barriers, HSCT cardiotoxicity, exosome platforms, and the translational gaps still blocking routine clinical use.
Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.
Found an issue in this paper? Email admin@saimsara.com

Evidence preview · Did you know?
Realistic cardiovascular care scene showing a patient with refractory angina and regenerative therapy context.

No-option angina may be the clearest human signal

Did you know? In refractory angina, intramyocardial CD34+ therapy reduced angina frequency at 6 months, with RR 0.63.

This makes the evidence map especially relevant for patients beyond standard revascularization options.

Realistic cardiac surgery and imaging scene suggesting adjunct stem-cell therapy during coronary bypass surgery.

The benefit signal is real, but selective

Did you know? In ischemic heart disease patients undergoing CABG, adjunct CD34+/CD133+ cell implantation improved LVEF by 8.69 percentage points versus 1.43 in controls.

The full map separates this promising small-trial signal from larger studies with neutral primary endpoints.

Realistic translational research scene showing cardiac cell-delivery challenges, imaging, and laboratory safeguards.

The biggest obstacle may be delivery, not biology

Did you know? In dilated cardiomyopathy, myocardial retention of delivered CD34+ cells was only 0–1.44% early and 0–0.97% delayed.

This explains why imaging, biomaterials, exosomes, and delivery systems dominate the translation gap.

Swipe sideways on mobile · full evidence map opens after unlock

Abstract: To synthesize evidence regarding the efficacy, safety, and mechanistic pathways of stem cell-based interventions for cardiovascular conditions, including myocardial infarction (MI), heart failure (HF), and refractory angina. The review draws on 165 cited references, including 169 original outcome/effect studies, with 547679 total participants (topic deduplicated ΣN). Across the mapped evidence, autologous CD34+ and mesenchymal lineage therapies emerged as the most consistent signal, associated with observed LVEF improvement up to approximately 8.7% in selected ischemic heart disease/CABG settings and meaningful reductions in angina frequency, including a 6-month RR of 0.63 in refractory angina and improved coronary flow reserve from 2.08 to 2.68 in microvascular disease. Paracrine signaling, neovascularization, and immunomodulation recurred as dominant mechanistic themes, with cell-free exosome platforms and biomaterial-assisted delivery emerging as prominent strategies to overcome the very low myocardial retention (often <1.5%) that limits whole-cell approaches. The evidence map also highlights HSCT-related cardiovascular toxicity as a distinct concern, with around 30% of alloHSCT recipients developing cardiotoxicity and pediatric cohorts showing post-transplant hypertension in 38%. Patient-level modifiers such as diabetes-impaired CD34+ mobilization (r = -0.82) and nicotine-related MSC dysfunction indicate that comorbidity-aware patient selection and preconditioning may be practical levers to improve regenerative outcomes. Overall, the evidence supports stem cell therapy as a biologically plausible adjunct for ischemic heart disease and refractory angina, but heterogeneity in cell type, delivery route, and endpoints precludes definitive efficacy conclusions. Future research should prioritize standardized, adequately powered trials of hypoimmune iPSC derivatives, exosome-based therapeutics, and bioengineered delivery platforms in comorbidity-stratified populations to resolve the translational gaps identified in this map.

Keywords: Stem cell therapy; Cardiovascular disease; Myocardial infarction; Heart failure; Mesenchymal stem cells; Induced pluripotent stem cells; Regenerative medicine; Cardiotoxicity; Hematopoietic stem cell transplantation; Angiogenesis

Review Stats

Get access to the full paper

Unlock the full evidence map

The full evidence review, including the Introduction, Methods, Results, Discussion, Conclusion, figures, and complete reference index, opens after purchase or sign-in. The Evidence Object JSON is a separate machine-readable evidence product: a concentrated synthesis of results, topic-level evidence, and discussion across original and non-original studies. It can be directly input into your LLM, agent, or RAG workflow.

Reference Index (165)
Article views: —
Follow us

© 2026 SAIMSARA Journal Impressum Published by ML in Health Science GbR